Tier 2 — strong
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
Nature communications
2021
12(1):5616
Bibliography
- PubMed
- PMID 34556670
- PubMed Central
- PMC8460738
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Supported by Chinese national research programs, the Kobayashi International Scholarship Foundation, an MSD scholarship donation and a Gunma University joint program.
- Competing interests
- The authors declared no competing interests.
Study snapshot
| Design | Randomized double-blind crossover phase I clamp study with preclinical experiments |
|---|---|
| Model | Human participants; see population |
| Sample | 15 healthy men in the human clamp trial; separate mouse/cell experiments |
| Intervention | Single-dose berberine versus placebo during a hyperglycemic clamp; KCNH6 experiments |
| Duration | 160-minute human clamp; 14-day adverse-event follow-up |
| Endpoints | Insulin and C-peptide during hyperglycemic clamp; KCNH6 channel function; Mouse glucose/insulin responses |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine for Blood Sugar: Diabetes, Insulin Resistance and HbA1cReview berberine for blood sugar, HbA1c, insulin resistance and prediabetes. Compare controlled trials, real effect sizes, monitoring and safety.Read analysis
- Berberine Side Effects: Digestive Symptoms and Long-Term SafetyUnderstand berberine side effects, digestive complaints, glucose concerns, heart-rhythm reports, long-term safety limits and when to seek medical help.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
